ArticleNaunyn-Schmiedeberg's archives of pharmacology2026
Imeglimin halts cyclophosphamide-induced ovarian injury: a dual modulation of TLR4/NF-κB/NLRP3-driven inflammation and AMPK/SIRT1/PGC-1α pathways.
Article in Naunyn-Schmiedeberg's archives of pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cyclophosphamide (CPA) induces premature ovarian insufficiency (POI) through oxidative stress, inflammation, pyroptosis, and apoptosis, posing a significant fertility risk in cancer survivors; this study investigates imeglimin's protective effects against CPA-induced POI in female rats by modulating TXNIP-NLRP3 inflammasome activation and AMPK/SIRT1/PGC-1α signaling. Female rats were divided into four groups: control, imeglimin (IMEG) alone, CPA, and CPA + IMEG. Body/ovarian weights and estrous cycles were monitored, with serum estradiol, FSH, and AMH measured by ELISA. Oxidative stress (MDA, GSH, CAT), inflammation (TNF-α, IL-18, IL-1β by ELISA; NF-κB by IHC), apoptosis (cleaved caspase-3), and signaling pathways (TXNIP, NLRP3, caspase-1, p-AMPK, SIRT1, PGC-1α by Western blot; TLR4, MYD88, ASC, GSDMD, Bax, Bcl-2 by qRT-PCR) were assessed. CPA significantly reduced body/ovarian weights, disrupted estrous cycles, lowered estradiol/AMH while elevating FSH, increased MDA but decreased GSH/CAT, upregulated NF-κB/TNF-α/IL-18/IL-1β/cleaved caspase-3, and enhanced TXNIP/NLRP3/caspase-1/TLR4/MYD88/ASC/GSDMD/Bax while suppressing Bcl-2, resulting in a significantly higher Bax/Bcl-2 ratio, p-AMPK/SIRT1/PGC-1α. IMEG co-treatment reversed these changes, restoring weights/cycles/hormones, attenuating oxidative/inflammatory/apoptotic markers, inhibiting NLRP3 inflammasome/pyroptosis pathways, and activating p-AMPK/SIRT1/PGC-1α signaling. Imeglimin attenuates CPA-induced premature ovarian insufficiency via inhibition of oxidative, inflammatory, and pyroptotic damage and p-AMPK/SIRT1/PGC-1α activation, as evidenced by preservation of ovarian structural integrity, follicular architecture, and endocrine markers. These findings highlight its potential as a candidate for chemotherapy-associated ovarian protection, pending further validation through direct fertility outcome studies.
Indexed as
Identifiers
42728409What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.